Opioid Analgesics Market projected to total US$ 65.8 Bn in 2031

As per a recent market analysis by Future Market Insights (FMI), demand in the Opioid Analgesics Market is slated to increase at a 5.4% CAGR, reaching a valuation of US$ 39.0 Bn in 2021.

Rising demand for post-surgery pain management and improvements in drug formulations to reduce side effects of analgesics are expected to continue driving sales of Opioid Analgesics over the forecast period.

Sales of morphine are anticipated to command 13% of the overall Opioid Analgesics Market share, and the market valuation is projected to total US$ 65.8 Bn in 2031, opines FMI.

Opioids are a type of narcotic pain medication used to treat moderate to severe pain, such as diarrhea suppression, cough suppression, anesthesia, cancer pain, injury or trauma, surgical pain, and neuropathic pain.

Request a sample to obtain authentic analysis and comprehensive market insights at- https://www.futuremarketinsights.com/reports/sample/rep-gb-14043

Increasing incidence of chronic conditions such as cancer and chronic pulmonary obstructive disease (COPD) in the geriatric population is spurring demand for opioid analgesics. Opioids effectively help in post-operative pain management and pain caused by orthopedic disorders, resulting in high demand for the same.

As per the American Cancer Society, the global incidence of cancer was 19.3 million in 2020. According to the National Cancer Institute, 20% to 50% of cancer patients suffer from pain continuous pain.

Around 80% of patients suffering from advanced-stage cancer have severe pain. By 2030, the global burden of cancer is expected to grow to 21.7 million new cancer cases, majorly because of the growing aging population. As a result, sales of opioid analgesics are projected to rise in tandem.

Opioid analgesics are effective in relieving pain; however, excess consumption of opioids can result in mental and physical dependency. In response to this, manufacturers are investing in research and development to launch non-addictive opioid variants.

Discover more about report analysis with figures and data tables, along with the table of contents. Ask an Analyst- https://www.futuremarketinsights.com/ask-question/rep-gb-14043

Key Takeaways:

  • Based on drug class, the oxycodone segment is expected to hold a market share of 19.7% in 2020.
  • In terms of indication, the surgical pain segment is projected to hold 45.5% of the total opioid analgesics market share.
  • The oral route of administration segment is expected to expand at a 6.5% CAGR through 2031.
  • Sales of opioid analgesics through hospital pharmacies are projected to generate revenues worth Us$ 23,355.2 Mn by 2031.
  • The U.S. is projected to lead the North America opioid analgesics market, capturing 86% of the total market share in 2021.
  • Germany will emerge as a lucrative market with sales growing at a 3.8% CAGR in 2021.
  • The U.K. is projected to lead the Europe opioid analgesics market, expanding at a 4.7% CAGR through 2031.
  • China is anticipated to account for 54.2% of the East Asia opioid analgesics market share in 2021.
  • Sales of opioid analgesics in India are expected to account for 35.4% of the South Asia market share in 2021.
  • Japan opioid analgesics market is projected to expand at a 5.6% CAGR, and South Korea will account for 14.5% of the East Asia market share.

“Increasing adoption of opioid maintenance treatment (OMT) to treat opioid dependence (OD), along with availability of opioid medications through online retail channels will continue providing tailwinds to opioid analgesics sales,” says an FMI analyst.

Contact Sales for Further Assistance in Purchasing this Report- https://www.futuremarketinsights.com/checkout/14043

Competitive Landscape

Leading companies operating in the global opioid analgesics market are investing in research and development to launch commercially available and non-addictive opioids in the market to gain a competitive edge. Apart from this, mergers, acquisitions, and collaborations will remain a part of prominent growth strategies used by market players. Fos instance:

  • In September 2018, Novartis, an international healthcare organization, signed an agreement for the marketing, sales, and distribution of well-known pain medicine brands Voltaren (diclofenac sodium) and Cataflam (diclofenac potassium) in Malaysia, Thailand, and the Philippines.

Leave a comment

Your email address will not be published. Required fields are marked *